Trials / Active Not Recruiting
Active Not RecruitingNCT06926842
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Zealand Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Petrelintide | Petrelintide will be taken by participants once weekly subcutaneously. |
| OTHER | Placebo | Matching placebo to petrelintide will be taken by participants once weekly subcutaneously. |
Timeline
- Start date
- 2025-04-22
- Primary completion
- 2026-08-13
- Completion
- 2026-08-13
- First posted
- 2025-04-15
- Last updated
- 2026-01-15
Locations
48 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06926842. Inclusion in this directory is not an endorsement.